Efficacy and safety of inetetamab-containing regimens in patients with HER2-positive metastatic breast cancer: a real-world retrospective study in China

Efficacy and safety of inetetamab-containing regimens in patients with HER2-positive metastatic breast cancer: a real-world retrospective study in China

BackgroundInetetamab (cipterbin) is an innovative anti-HER2 humanized monoclonal antibody. The efficacy and safety of a combination of inetetamab and vinorelbine in the first-line treatment of human epidermal receptor positive (HER2+) metastatic breast cancer (MBC) have been confirmed. We aimed to i...

Full description

Bibliographic Details
Main Authors: Xiaoyu Liu, Peng Zhang, Chao Li, Xiang Song, Zhaoyun Liu, Wenna Shao, Sumei Li, Xinzhao Wang, Zhiyong Yu
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-06-01
Series:Frontiers in Oncology
Subjects:
breast cancer
inetetamab
human epidermal receptor 2 positive
monoclonal antibody
real-word data
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1136380/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1136380/full

Similar Items